secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2023-01-12T23:59:59+00:00
Accession:  0001493152-23-001237
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Matinas BioPharma partners with Resilience to explore oral nucleic acid delivery via LNC platform
--------------------------------------------------------------------------------

- Material Transfer and Evaluation Agreement with National Resilience for oral delivery of nucleic acids.
- Research program includes design, formulation, optimization, and in vitro/in vivo testing of nucleic acids with LNC platform.
- Collaboration is distinct from ongoing work with BioNTech, allowing simultaneous platform development.
- No financial terms disclosed; partnership aims to demonstrate LNC platform capabilities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315223001237/0001493152-23-001237-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315223001237/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-001237

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer